Intrinsic Mechanism Of Anticancer Drugs In Neurodegenerative Disorders - 9781916706217

Neurodegenerative (NDDs) disorders are one of the most alarming medical illnesses affecting the brain and nervous system. The Lack of understanding of the disease-leading mechanisms makes the treatment options unavailable. Currently, an estimated 35.6 million people are surviving with Dementia, and the number is presumed to triple by the next 30 years [1]. According to the report of the World Health Organization (WHO), in the next 20 years, NDDs affecting motor functions will be the second most widespread reason for human death [2]. NDDs are categorized based on clinical features- dementia, parkinsonism, or motor neuron disease, or based on the anatomic areas covered- spinocerebellar degeneration, frontotemporal degeneration and extrapyramidal disorders. In general, synucleinopathies, and TDP-43 proteinopathies are the most widespread NDDs. Abnormal protein aggregation is the major hallmark feature of all NDDs associated with some fundamental processes such as progressive neuronal loss, neuroinflammation, dysfunction of the Ubiquitin proteasome system (UPS), abnormal autophagic processes, oxidative insult, and neuronal apoptosis (HD), and Multiple sclerosis (MS) are the major NDDs affecting the global health. Aging is the biggest risk factor for various diseases, from cancer to NDDs. These agerelated diseases can be categorized into two groups. Loss-of-function diseases like NDDs are represented by the loss of cells, tissues, or optimal physiological functions. While gainof- function diseases like cancer exhibit gain of cells and, sometimes, new cellular functions

• | Author: Dia Advani
• | Publisher: Self Publish
• | Publication Date: Jun 25, 2023
• | Number of Pages: 232 pages
• | Language: English
• | Binding: Paperback
• | ISBN-10: 1916706215
• | ISBN-13: 9781916706217